Overexpression of CEBPA genes was observed in 88% (7/8 of the presentation samples) of the patients with concurrent biallelic mutations (Patients DX5 and DX8), supporting the notion that haematopoietic resistance is evident in the pathogenesis of AML-NK (Figure 6). The gene discussed is CEBPA; the disease is acute myeloid leukemia.